Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists

QJM: An International Journal of Medicine

Volumn 104, Issue 8, 2011, Pages 721-722

  Iglesias, P ^a   Diez J J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; QUINAGOLIDE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; GROWTH HORMONE DEFICIENCY; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS ADENOMA; INSULIN HYPOGLYCEMIA; MALE; NOTE; PRIORITY JOURNAL; PROLACTINOMA; REMISSION; TUMOR VOLUME; VISUAL FIELD; ARTICLE; DOSE RESPONSE; HYPOPHYSIS; HYPOPHYSIS TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; COMBINED MODALITY THERAPY; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEADACHE; HUMANS; MALE; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTINOMA; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84855720836     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq130     Document Type: Note

References (5)

1. Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 2010; 10: 10.
2. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med 2010; 362: 1219-26.
3. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006; 65: 265-73.
4. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol 2007; 67: 426-33.
5. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab 2007; 92: 2861-5.